

Uncomplicated type B acute aortic dissection: endovascular repair or best medical treatment?

Patients with uncomplicated type B acute aortic dissection (type B-AAD) are commonly treated with conservative therapy (best medical treatment [BMT]) although the long-term outcome of medical therapy alone is suboptimal, with a reported 30% to 50% mortality rate at 5 years and a delayed expansion of the false lumen in 20% to 50% of patients at 4 years. Thoracic endovascular aortic repair (TEVAR) has been also used in patients with uncomplicated type B-AAD to reduce late morbidity and mortality. Recently, several studies have compared early and late outcomes of TEVAR and BMT in patients with type B-AAD. However, the results following preemptive TEVAR for uncomplicated type B-AAD in the acute setting require long-term observation to determine the benefits.





Fig. 1. In a retrospective study of 338 patients with uncomplicated type B acute aortic dissection (B-AAD), management strategies involving thoracic endovascular aortic repair (TEVAR) and best medical treatment (BMT) were compared.

1/3



In our study, the early event rate in the TEVAR group was 10.3%, which was higher than that of the BMT group (4.5%), although the difference was not statistically significant. In the TEVAR group, most of the early events (17 of 19) seemed minor or transient, but regular surveillance was warranted if type I endoleak presented. In the BMT group, 4 major complications (1 organ failure and 3 ruptures) occurred, plus 3 uncomplicated dissections became complicated despite aggressive antihypertensive management. The early mortality rate was 0.5% with TEVAR and 2.6% with BMT, and no significant was found between two groups.

In our study, patients in the BMT group experienced more aortic-related adverse events and late deaths than those treated with TEVAR. The cumulative freedom from aortic-related adverse events at 5-year follow-up was 71.8% in the TEVAR group and 62.2% in the BMT group. Type I endoleak (11 of 35; 31.4%) and stent graft-induced new entry ?SINE? (9 of 35; 25.7%) were the main late events in patients treated with TEVAR, and the main causes of late events in patients treated with BMT were aortic enlargement (28 of 59; 47.5%) and aortic rupture (19 of 59; 32.2%) . The cumulative survival rates from all causes of death at the fifth year was 89.2% in the TEVAR group and 85.7% in the BMT group. A total of 50 late deaths were reported, including 27 aortic-related late deaths, 24 of which were due to a ruptured false lumen in the descending aorta and the remaining 3 to retrograde type A-AD.

This study confirmed the feasibility of TEVAR for uncomplicated type B-AAD in the acute setting with lower aortic-related adverse events and a lower mortality rate compared with BMT after 5 years of follow-up. Given that the TEVAR procedure did not significantly lower morbidity and mortality compared with BMT during the early years of follow-up, TEVAR should be considered as a therapy to improve late outcomes in young adults or patients with longer life expectancy.

Yong-Lin Qin¹, Feng Wang², Tian-Xiao Li³, Wei Ding¹, Gang Deng¹, Bo Xie¹, Gao-Jun Teng¹

¹Center of Interventional Radiology and Vascular Surgery, Department of Radiology, Zhongda Hospital, School of Medicine, Southeast University, Nanjing, China ²Department of Interventional Radiology,



Atlas of Science another view on science http://atlasofscience.org

the First Affiliated Hospital of Dalian Medical University, Dalian, China ³Department of Interventional Radiology, Henan Provincial People's Hospital, Zhengzhou University, Zhengzhou, China

Publication

Endovascular Repair Compared With Medical Management of Patients With Uncomplicated Type B Acute Aortic Dissection.

Qin YL, Wang F, Li TX, Ding W, Deng G, Xie B, Teng GJ J Am Coll Cardiol. 2016 Jun 21

3/3